loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Alembic Pharma's Q1FY27 revenues grew ~26% YoY

ICICIdirect Research 05 Aug 2026 DISCLAIMER

News: Alembic Pharma's Q1FY27 revenues grew ~26% YoY to ₹ 2150 crore, driven by the US business which grew 49% to ₹778 crore. RoW Business also grew ~17% to ₹383 crore Domestic formulations business, on the other hand, continued to be remained on a slower path with just ~7% growth to ₹642 crore, despite industry tailwinds. API business witnessed growth of 32.6% on Lower base to ₹346 crore. EBITDA grew ~18% YoY to ₹ 331.9 crore and margins stood at 15.4% (101 bps de-growth mainly due to elivated R&D cost) mainly due to GPM contraction of 503 bps(71.2%). PAT grew by ~11.6% YoY to ₹172 crore.

View: Tepid growth in the domestic business was due to continued slowdown in Acute therapies (~57% of India business) which grew mere 5%, thus neutralising ~24% growth in Animal healthcare (~22% of India business). Specialty business (~21% of the India business) also remained flat. US growth was driven by 7 new product launches and market share gains across select therapies. Company has plans to launch few meaningful products in FY27 for US while new US branded business (Pivya) is also scaling up gradually. Management for FY27 has guided for low-double-digit growth in FY27 to be supported by mid-teens growth in ROW and 10-15% growth in the US business while India growth in line with IPM. With the kind of momentum in India, matching with IPM growth of 11-12% looks demanding. Overall, despite exports traction, below-par India growth, and below-par EBITDA margins likely to weigh

Impact: Neutral

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere